Show simple item record

Pathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular Effectors

dc.contributor.authorFerrara, James L. M.en_US
dc.date.accessioned2009-07-10T18:58:25Z
dc.date.available2009-07-10T18:58:25Z
dc.date.issued2000-06-01en_US
dc.identifier.citationFerrara, James L.M. (2000). "Pathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular Effectors." Journal of Hematotherapy & Stem Cell Research 9(3): 299-306 <http://hdl.handle.net/2027.42/63129>en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/63129
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10894351&dopt=citationen_US
dc.description.abstractThe pathogenesis of acute graft versus host disease (GVHD) is multistep process. This review considers acute GVHD in three sequential steps: conditioning regimen, donor T cell activation, and effector mechanisms. In step one, the conditioning regimen simultaneously damages and activates host tissues, amplifying antigen presentation to allogeneic donor T cells. In step two, donor T cells, activated by host alloantigens, proliferate and secrete a variety of cytokines. Type 1 cytokines (interleukin-2 and interferon-γ) are critical for acute GVHD, but several regulatory mechanisms of tissue damage include inflammatory cytokines and cytolytic cellular effectors. The gastrointestinal (GI) tract is a principal target organ because damage to the GI mucosa can release inflammatory mediators such as endotoxin that amplify systemic disease. The inflammatory processes of acute GVHD can be considered as a distortion of the cellular responses to viral and bacterial infections. Cell-mediated toxicity is critical to other GVHD target organs, particularly the liver, where Fas-mediated injury predominates. The cytolytic pathways (e.g., perforin) clearly intensify acute GVHD, although they are not necessary for systemic disease in several model systems. Many of these insights come from animal models using mutant mouse strains that can clarify the role of individual proteins or cell types in the disease process. These insights should allow the testing of new classes of drugs and inhibitors in clinical bone marrow transplantation.en_US
dc.format.extent251446 bytes
dc.format.extent2489 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMary Ann Liebert, Inc., publishersen_US
dc.titlePathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular Effectorsen_US
dc.typeArticleen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid10894351en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/63129/1/15258160050079407.pdf
dc.identifier.doidoi:10.1089/15258160050079407en_US
dc.identifier.sourceJournal of Hematotherapy & Stem Cell Researchen_US
dc.identifier.sourceJournal of Hematotherapy & Stem Cell Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.